Swedish biotech company Salipro Biotech has entered into a collaboration and licensing agreement with AbCellera for access to its proprietary Salipro Platform, which stabilises challenging G protein coupled receptor (GPCR), ion channel and transporter antigens.
“We are excited to build on the success of our previous studies and deepen our relationship with the team at AbCellera,” said Jens Frauenfeld, CEO of Salipro Biotech. “We look forward to deploying our expertise and our platform technology to generate Salipro-stabilised antigens of challenging membrane proteins to enable AbCellera’s discovery programmes against these drug targets.”
